iCoat Medical AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys
Phase 2
Not yet recruiting
- Conditions
- Ischemia-reperfusion InjuryKidney Transplant; Complications
- Interventions
- Drug: iCM012 solution 2 mg/mLDrug: Placebo
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- iCoat Medical AB
- Target Recruit Count
- 200
- Registration Number
- NCT06582485
FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation
Phase 1
Completed
- Conditions
- Kidney Transplant; ComplicationsIschemia-reperfusion Injury
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- iCoat Medical AB
- Target Recruit Count
- 18
- Registration Number
- NCT05246618
- Locations
- 🇸🇪
Skane University Hospital, Malmö, Sweden
© Copyright 2025. All Rights Reserved by MedPath